Surgery for multiple endocrine neoplasia type 1-associated primary hyperparathyroidism

The British Journal of Surgery
J WaldmannD K Bartsch

Abstract

Surgery in patients with multiple endocrine neoplasia type 1 (MEN1)-associated primary hyperparathyroidism (pHPT) is difficult as the condition it is caused by asymmetrical multiple gland hyperplasia. It is uncertain which operative procedure provides the best outcome with regard to long-term normocalcaemia. All patients who had surgery for genetically confirmed MEN1-associated pHPT between 1987 and 2009 were identified from a prospective database. Clinical data, operative procedures and outcome were analysed retrospectively. A total of 47 patients were identified. Twenty-three patients underwent total parathyroidectomy with thymectomy and autotransplantation (TPTX + AT), 11 patients subtotal parathyroidectomy (3-3.5 glands, SPTX) with thymectomy, and 13 patients selective gland excision (fewer than 3 glands, SGE). Rates of persistent disease, recurrent disease and permanent hypoparathyroidism after TPTX + AT were 4 per cent (1 patient), 4 per cent (1 patient) and 22 per cent (5 patients) respectively. Respective rates after SPTX were 0 per cent, 18 per cent (2 patients) and 45 per cent (5 patients), which were not statistically different from those following TPTX + AT. SGE resulted in persistent disease in 23 per cent (3 patie...Continue Reading

References

Jun 1, 1976·Archives of Surgery·J J Livesay, D G Mulder
Oct 1, 1976·Annals of Surgery·O H ClarkT K Hunt
Nov 1, 1991·World Journal of Surgery·P K WagnerM Rothmund
Apr 18, 1997·Science·S C ChandrasekharappaS J Marx
Nov 20, 1998·European Journal of Endocrinology·D BartschB Simon
Sep 7, 2001·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·M KataiK Hashizume
Dec 12, 2001·The Journal of Clinical Endocrinology and Metabolism·M L BrandiS J Marx
Mar 1, 1954·The American Journal of Medicine·P WERMER
May 29, 2004·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·P LangerD K Bartsch

❮ Previous
Next ❯

Citations

Feb 15, 2011·International Journal of Endocrinology·Grzegorz PiechaAndrzej Więcek
Dec 1, 2014·Surgical Pathology Clinics·Peter M SadowVania Nosé
Oct 10, 2015·Langenbeck's Archives of Surgery·Maurizio IacoboneMenno Vriens
Sep 10, 2013·Surgical Oncology Clinics of North America·Scott K Sherman, James R Howe
Sep 12, 2015·Annals of Surgical Oncology·Melissa M BoltzJudy Jin
Jan 3, 2013·Asia-Pacific Journal of Clinical Oncology·Richard W Carroll
Aug 13, 2013·Molecular and Cellular Endocrinology·Rajesh V Thakker
Feb 23, 2011·Arquivos brasileiros de endocrinologia e metabologia·Cesar Luiz BoguszewskiTeresa Cristina Santos Cavalcanti
Jan 5, 2019·Thyroid : Official Journal of the American Thyroid Association·Katherine A HillKelly L McCoy
Jun 23, 2012·The Journal of Clinical Endocrinology and Metabolism·Rajesh V ThakkerUNKNOWN Endocrine Society
Oct 19, 2019·Clinical Endocrinology·Jerena ManoharanDetlef K Bartsch
Nov 20, 2020·International Journal of Surgery Case Reports·Diani KartiniMaria Francisca Ham
Apr 12, 2021·Annales d'endocrinologie·Aurore GeslotDelphine Vezzosi
Apr 29, 2021·AJR. American Journal of Roentgenology·Arafat AliSherry S Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.